{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:30:07Z","timestamp":1794961807751,"version":"4.9.1"},"reference-count":17,"publisher":"Oceanside Publications Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease of the nasal and paranasal sinuses. In phase III clinical trials, dupilumab significantly improved objective and patient-reported measures of CRSwNP versus placebo.\n However, a real-world evidence gap exists between efficacy and effectiveness data for dupilumab in CRSwNP, particularly in the United States.  <jats:bold>Objective:<\/jats:bold> Assessing Long-teRm Outcomes of dupiluMAb Treatment in Adult Patients With CRSwNP (AROMA) aims to characterize patients\n who receive dupilumab for CRSwNP in a real-world setting and evaluate long-term effectiveness.  <jats:bold>Methods:<\/jats:bold> AROMA is a prospective global registry study that is recruiting adult patients with uncontrolled CRSwNP who were initiating dupilumab and following them for up to 36\n months. Baseline demographics and disease characteristics were assessed for all patients entering the registry.  <jats:bold>Results:<\/jats:bold> As of February 2023, the study had recruited 303 patients of a target enrollment of 700, with a mean age of 50.8 years, and 57.1% were recruited in the\n United States. A history of asthma was reported in 70.6% of the patients and a history of allergic rhinitis in 70.6% of the patients. In the 24 months before enrollment, 61.7% of the patients had at least one sinonasal surgery and 68.6% used systemic corticosteroids. At baseline, 35.0% of\n the patients were receiving intranasal corticosteroids and 33.3% were receiving leukotriene receptor antagonists. In the Global Patient Assessment, 31.7% and 29.7% of the patients reported moderate and severe CRSwNP symptoms, respectively, during the past week.  <jats:bold>Conclusion:<\/jats:bold>\n Patients in AROMA had a high disease burden in terms of symptoms, comorbidities, and treatment burden. Nearly two-thirds of patients with CRSwNP had at least one sinonasal surgery before initiating dupilumab.Clinical trial NCT04959448 (AROMA), &lt;ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"\n ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\"&gt;www.clinicaltrials.gov&lt;\/ext-link&gt;<\/jats:p>","DOI":"10.2500\/aap.2025.46.250055","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:36:17Z","timestamp":1758083777000},"page":"414-421","source":"Crossref","is-referenced-by-count":2,"title":["Baseline disease characteristics among patients with chronic rhinosinusitis with nasal polyps in AROMA: A global registry study"],"prefix":"10.2500","volume":"46","author":[{"given":"Anju T.","family":"Peters","sequence":"first","affiliation":[{"name":"From the Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagenmann","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, D\u00fcsseldorf University Hospital (UKD), D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeharu","family":"Fujieda","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University of Fukui, Fukui, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Nash","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Clotz","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Corbett","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi, Morristown, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Radwan","sequence":"additional","affiliation":[{"name":"Immunology and Inflammation, Regeneron Pharmaceuticals Inc., Uxbridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","article-title":"Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis","volume":"36","author":"Chen","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","first-page":"151","article-title":"State-of-the-art overview on biological treatment for CRSwNP","volume":"59","author":"Hellings","year":"2021","journal-title":"Rhinology"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B9","first-page":"25","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharmaceut Med"},{"key":"B10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/picr.PICR_36_18","article-title":"Real world evidence (RWE) - are we (RWE) ready?","volume":"9","author":"Suvarna","year":"2018","journal-title":"Perspect Clin Res"},{"key":"B11","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/all.15134","article-title":"Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"77","author":"van der Lans","year":"2022","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"crossref","first-page":"00085\u201302022","DOI":"10.1183\/23120541.00085-2022","article-title":"AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"8","author":"Siddiqui","year":"2022","journal-title":"ERJ Open Res"},{"key":"B14","doi-asserted-by":"crossref","first-page":"e0127228","DOI":"10.1371\/journal.pone.0127228","article-title":"Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the united airways concept further supported","volume":"10","author":"H\u00e5kansson","year":"2015","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMcibr1514013","article-title":"Aspirin-exacerbated respiratory disease\u2013new prime suspects","volume":"374","author":"Laidlaw","year":"2016","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/jcm13041066","article-title":"Adherence to intranasal steroids in chronic rhinosinusitis with nasal polyposis prior to and during biologic therapy: a neglected matter","volume":"13","author":"Norelli","year":"2024","journal-title":"J Clin Med"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000005\/art00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:39:23Z","timestamp":1759552763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"alternative-id":["1088-5412(20250901)46:5L.414;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250055","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}